Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have resumed across the world after confirmation it is safe to do so.
List view / Grid view
University of Oxford
Filter the results
The COVID-19 pandemic initiated a huge pharmaceutical effort to tackle the virus at the cause, resulting in a surge in innovation in vaccines and antiviral drugs. This is an R&D trend that is likely to continue in an attempt to protect ourselves from future outbreaks. In this article, IP Analyst…
A clinical trial in the UK has shown that lopinavir-ritonavir is not an effective treatment for patients admitted to hospital with COVID-19.
Prime Minister Boris Johnson visited the construction site of the VMIC and met scientists and engineers at the forefront of the UK’s COVID-19 response.
Prashant Khadayate, Pharma Analyst at GlobalData, explains what the current state of the COVID-19 pandemic is in India and what vaccine options are currently under development/testing.
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.
After the clinical trial for AZD1222 was halted last week, the studies for AstraZeneca's COVID-19 vaccine candidate will now resume.
Data released from the Phase I/II trial of the ChAdOx1 COVID-19 vaccine candidate suggests it elicits an immune response with no adverse effects.
The government has entered partnerships with Pfizer and Valneva to secure doses of several promising COVID-19 vaccines and secured COVID-19 neutralising antibody treatments from AstraZeneca.
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
A clinical trial has shown that an inexpensive steroid called dexamethasone could prevent death in one out of eight ventilated COVID-19 patients and one out of 25 patients receiving oxygen only.
The vaccine alliance said the Covax AMC programme is the first in a series of financing programmes to ensure low- and middle-income countries will have access to COVID-19 vaccines.
Advent announced it has manufactured and delivered the first 4,000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.
A new agreement between the University of Oxford and AstraZeneca will allow the former's COVID-19 vaccine candidate to be manufactured and distributed.
The UK Bioindustry Association industry-led vaccine manufacturing group has welcomed a £14 million investment to support COVID-19 vaccine manufacturing.